Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Drugs In Development, 2022, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.
H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 7, 11, 5, 15 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase I and Preclinical stages comprises 3, 1 and 3 molecules, respectively.
Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Influenza A Virus, H3N2 Subtype Infections - Overview
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
Influenza A Virus, H3N2 Subtype Infections - Drug Profiles
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products
Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
Featured News & Press Releases
Mar 15, 2022: First Participants dosed in phase 2a study of pan-antiviral nasal spray
Jan 05, 2022: Zosano Pharma announces publication of clinical data demonstrating comparable immunogenicity of a Trivalent Influenza Vaccine formulated on its transdermal microneedle system versus an intramuscular injection of the vaccine at a higher dose
Aug 31, 2021: FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal) vaccine now available in the US for annual flu season
Aug 02, 2021: FluGen announces publication of positive results from phase 2 human challenge study of its M2SR vaccine candidate against highly drifted strain of H3N2 influenza virus
Jul 01, 2021: FluGen awarded US Department of Defense funding to conduct clinical study evaluating investigational M2SR flu vaccine and current standard-of-care high dose vaccine
May 25, 2021: FluGen initiates NIH-funded trial of M2SR flu vaccine; first study in adults up to age 85
Aug 13, 2020: AstraZeneca ships FLUMIST QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season
Feb 25, 2020: Novavax’ Preclinical NanoFlu Data published in vaccines; details structural basis for broadly neutralizing immunity
Nov 04, 2019: Sanofi: FDA approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
Oct 16, 2019: Novavax begins Phase III clinical trial for influenza vaccine NanoFlu
Jun 27, 2019: Novavax confirms accelerated approval pathway available for licensure of Nanoflu
Feb 12, 2019: FluGen’s M2SR Influenza Vaccine succeeds in phase 2 human challenge trial against a highly mismatched virus
Jan 03, 2019: Novavax announces positive phase 2 NanoFlu results in older adults
Dec 05, 2018: Next generation cell-based influenza vaccine shows significantly greater effectiveness compared to standard egg-based options in the 2017-18 US Influenza Season
Nov 16, 2018: Seqirus announces U.S. $140 Million manufacturing expansion to meet growing demand for innovative cell-based influenza vaccines
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Alla Chem LLC, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Allergy Therapeutics Plc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AlphaVax Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Ansun Biopharma Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AstraZeneca Plc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AusBio Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by BlueWillow Biologics Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Brandenburg Antiinfektiva GmbH, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Chicago Biosolutions Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Cidara Therapeutics Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by CSL Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Emergent BioSolutions Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Ena Respiratory Pty Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Gamma Vaccines Pty Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by InvVax Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Ab&b Biotechnology Co Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Moderna Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by PrEP Biopharm Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Seqirus Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Serum Institute of India Pvt Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Trellis Bioscience Inc, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Vacthera BioTech GmbH, 2022
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Zosano Pharma Corp, 2022
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, 2022
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, 2022 (Contd..1)
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, 2022 (Contd..2)
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, 2022
List of Figures
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
